Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Effects of Ticagrelor on Myocardial Infarct Size

  • Hahn, Joo-Yong (Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • Received : 2017.07.18
  • Accepted : 2017.08.06
  • Published : 2017.09.30
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006;27:1038-47. https://doi.org/10.1093/eurheartj/ehi754
  2. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. https://doi.org/10.1056/NEJMoa0904327
  3. Storey RF, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007;50:1852-6. https://doi.org/10.1016/j.jacc.2007.07.058
  4. Nanhwan MK, Ling S, Kodakandla M, Nylander S, Ye Y, Birnbaum Y. Chronic treatment with ticagrelor limits myocardial infarct size: an adenosine and cyclooxygenase-2-dependent effect. Arterioscler Thromb Vasc Biol 2014;34:2078-85. https://doi.org/10.1161/ATVBAHA.114.304002
  5. Ye Y, Birnbaum GD, Perez-Polo JR, Nanhwan MK, Nylander S, Birnbaum Y. Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol 2015;35:1805-14. https://doi.org/10.1161/ATVBAHA.115.305655
  6. Armstrong PW, Siha H, Fu Y, et al. ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. Circulation 2012;125:514-21. https://doi.org/10.1161/CIRCULATIONAHA.111.047530
  7. Yun KH, Rhee SJ, Ko JS. Comparison of ticagrelor and clopidogrel on myocardial infarct size in patients undergoing primary percutaneous coronary intervention. Korean Circ J. 2017;47:705-13. https://doi.org/10.4070/kcj.2017.0044
  8. Khan JN, Greenwood JP, Nazir SA, et al. Infarct size following treatment with second- versus third-generation P2Y12 antagonists in patients with multivessel coronary disease at ST-segment elevation myocardial infarction in the CvLPRIT study. J Am Heart Assoc 2016;5:e003403.
  9. Kim EK, Park TK, Yang JH, et al. Ticagrelor versus clopidogrel on myocardial infarct size in patients undergoing primary percutaneous coronary intervention. J Am Coll Cardiol 2017;69:2098-9.
  10. Alexopoulos D, Xanthopoulou I, Gkizas V, et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797-804. https://doi.org/10.1161/CIRCINTERVENTIONS.112.972323